Purpose: We aimed to derive insights by analyzing the results of a patient safety awareness survey conducted by the Regional Patient Safety Center of the Korean Medical Association. Methods: Survey questions were developed in three domains: sociodemographic characteristics, patient safety awareness, and patient safety education needs. An online anonymous survey targeting Korean physicians was conducted annually from 2021 to 2023. Chi-square tests were used to verify differences in responses by year and sociodemographic characteristics. Results: A total of 774 physicians participated in the survey over the three-year period. Approximately half of the participants were still assessed to have insufficient knowledge about patient safety, and no clear year-over-year improvement was observed. Additionally, while patient safety incidents appeared common, the proportion of respondents who reported incidents remained around 20%. However, participants showed high levels of agreement or engagement in patient participation activities related to patient safety (over 90%), with 60% having previously received patient safety-related education, and nearly 90% expressing willingness to participate in future education. The findings also highlighted a particular urgency in improving patient safety awareness among clinic-based physicians. Conclusion Promoting awareness of patient safety incident reporting methods and encouraging clinic-based physicians to report incidents should be prioritized. The study’s findings will provide a foundation for more effectively fostering physician engagement in patient safety improvement activities.

Prostate cancer (PCa) typically occurs in older adults and generally has a relatively long survival period, making it challenging to demonstrate the effectiveness of treatment. In 2012, medical guidelines recommending against PCa screening using prostate-specific antigen (PSA) became widespread, as randomized controlled trials had not consistently shown survival benefits.Current concepts: In South Korea, awareness of PCa has historically been very low, and the rate of PSA test screening has consequently been lower than that in other major developed countries. Additionally, PSA screening has tended to occur within a limited framework accessible only to individuals already aware of the test. Given that PCa is a high-risk cancer predominantly affecting older men in South Korea, unconditionally following medical guidelines from the 2010s that took a negative stance toward PSA screening may exacerbate health inequalities, increase metastatic cancer incidence, and elevate cancer-specific mortality, particularly in light of Korea’s rapidly aging population. Thus, recent shifts in clinical guidelines in the early 2020s, advocating the proactive implementation of PSA-based screening tests as announced by various countries, are significant. These shifts provide additional support for policy responses aligned with Korea’s epidemiological context. Discussion and conclusion: We advocate for increased public discourse on national PCa screening policies. Such policies should be rationally designed to reduce the incidence of high-risk PCa while minimizing the potential harms associated with overdiagnosis and overtreatment.

This review explores the current status and future potential of digital therapeutics (DTx), emphasizing their role in clinical practice. It focuses on clarifying their classification, clinical applications, regulatory challenges, and prospective developments in the field.Current Concepts: Digital therapeutics are evidence-based interventions delivered via software to prevent, manage, and treat medical conditions. Unlike traditional pharmacotherapy, DTx products can be updated and modified, offering greater flexibility in treatment delivery. They are categorized into behavior-modification, physiological-modulation, and disease-management types, and are primarily applied to chronic conditions and neuropsychological disorders. Global regulatory frameworks are rapidly evolving to accommodate this burgeoning field.Discussion and Conclusion: Digital therapeutics offer significant advantages over traditional pharmacotherapy, such as lower development costs, personalized treatment options, and improved accessibility. These innovations have the potential to transform healthcare by complementing existing therapies and enabling data-driven, individualized care. However, several key challenges must be addressed for widespread adoption. Patient adherence remains inconsistent, particularly in longterm treatments, which can limit clinical effectiveness. In addition, underdeveloped reimbursement policies create economic uncertainty, and ongoing concerns regarding data security and privacy pose persistent risks. As technology advances, digital therapeutics are poised to enhance clinical outcomes, expand access to care, and transform traditional healthcare models, ultimately driving innovation in modern medicine.

Purpose: In Korea, the absence of a modified physical activity (PA) questionnaire specifically tailored for Koreans hinders the accurate assessment of PA among individuals with spinal cord injury (SCI). This study aimed to evaluate PA levels in individuals with SCI using a modified PA questionnaire and to provide insights into their PA patterns in Korea. Methods: A self-reported questionnaire was developed by revising and adapting the Korean version of the International Physical Activity Questionnaire (K-IPAQ) during an advisory meeting. Between April and June 2023, 176 individuals with SCI from metropolitan areas in Korea were recruited to assess their weekly PA. PA was quantified in Metabolic Equivalent Task-min/week (MET-min/week) by multiplying the reported PA duration. Results: The average PA level among individuals with SCI in Korea was 2,907.2±194.8 MET-min/week. By intensity, high-intensity activities accounted for 2,760.0±280.5 MET-min/week, moderate-intensity activities for 1,148.8±89.0 MET-min/week, and low-intensity activities for 1,869.4±110.3 MET-min/week. Approximately half of the participants met the World Health Organization (WHO) recommendations for PA. Conclusion Although Korean individuals with SCI demonstrated higher average PA levels compared to findings from other countries and the WHO recommendations, only about half of the participants met the WHO’s guidelines. These results underscore the need to strengthen efforts to promote PA participation among individuals with SCI.

Intravesical therapy is crucial in treating non-muscle invasive bladder cancer (NMIBC), aiming to prevent recurrence and progression following transurethral resection of bladder tumor. This review provides an overview of intravesical therapies, including Bacillus Calmette-Guérin (BCG), intravesical chemotherapy, and emerging treatment modalities.Current Concepts: BCG therapy remains the gold standard for high-risk NMIBC, significantly reducing recurrence and progression rates. However, managing BCG-unresponsive disease remains challenging and necessitates alternative treatment approaches. Intravesical chemotherapy, such as mitomycin C and gemcitabine, is frequently employed for intermediate-to-high-risk NMIBC and as a second-line therapy after BCG failure. Recent advancements have introduced novel intravesical approaches aiming to overcome BCG resistance and enhance treatment efficacy. Innovative methods, including viral gene therapy and nogapendekin alfa-inbakicept, are being studied for their potential to improve tumor eradication while minimizing toxicity. These strategies aim to increase immune activation, increase drug penetration, and reduce recurrence rates in NMIBC.Discussion and Conclusion: Despite advances, optimizing intravesical treatment selection remains challenging. While BCG therapy is effective, resistance and side effects limit its utility, necessitating alternative therapies. Intravesical chemotherapy is beneficial but suboptimal for high-risk NMIBC. Emerging therapies offer promising solutions for BCG-unresponsive NMIBC. Future research should focus on biomarker-driven treatment and combination strategies to enhance clinical outcomes. As new treatments emerge, intravesical therapy will continue to play a pivotal role in managing NMIBC.

Muscle-invasive bladder cancer (MIBC) is an aggressive cancer with a high recurrence risk due to micrometastases. Standard treatment, neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, is not suitable for all patients, with many being ineligible or experiencing recurrence, alongside significant toxicity concerns.Current Concepts: The introduction of immune checkpoint inhibitors (ICIs) into the perioperative setting —including neoadjuvant ICI use in cisplatin-ineligible patients, adjuvant ICI use in high-risk individuals, and chemoimmunotherapy in either the preoperative or postoperative period—has demonstrated promising clinical outcomes. Additionally, bladder preservation strategies are currently under investigation in select patients who exhibit favorable treatment responses, aiming to maintain quality of life without compromising oncologic outcomes. Nevertheless, challenges such as overtreatment, long-term toxicity, and immune-related adverse events remain significant, underscoring the necessity for precise patient selection.Discussion and Conclusion: To personalize perioperative management of MIBC, it is essential to develop and clinically implement robust predictive biomarkers. Assessment of molecular residual disease using circulating tumor DNA is emerging as a promising method to stratify risk, guide adjuvant treatment decisions, and monitor therapeutic response in real time. Future research should prioritize the validation of these biomarkers, refinement of patient selection criteria for bladder preservation strategies, and evaluation of novel therapeutic agents such as antibody-drug conjugates and fibroblast growth factor receptor inhibitors in the perioperative setting. Ultimately, adopting a precision oncology approach will be critical for balancing oncologic efficacy with toxicity management and achieving patient-centered outcomes.

Metastatic bladder cancer has historically been treated with platinum-based chemotherapy as the standard firstline therapy. Since the introduction of cisplatin-based regimens, advancements in treatment strategies have been limited. However, the recent emergence of immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) has significantly transformed the treatment landscape. Notably, the combination of enfortumab vedotin (EV) and pembrolizumab has demonstrated considerable clinical benefits, challenging traditional chemotherapy. This review aims to provide an overview of recent advancements in the treatment of metastatic bladder cancer.Current Concepts: Recent phase III clinical trials, notably EV-302/KEYNOTE-A39 and CheckMate 901, have reshaped the first-line management. EV combined with pembrolizumab has shown superior progression-free survival and overall survival compared to platinum-based chemotherapy, establishing it as a new standard of care. Patients ineligible for this regimen due to underlying comorbidities or toxicity may still benefit from alternative options. Such alternatives include platinum-based chemotherapy with ICI maintenance therapy, including avelumab or nivolumab. The selection of treatments should be individualized, taking into account specific patient factors, particularly platinum eligibility, renal function, and performance status.Discussion and Conclusion: The incorporation of ICIs and ADCs into the therapeutic landscape for metastatic bladder cancer has significantly improved patient outcomes. EV plus pembrolizumab has demonstrated substantial survival benefits, establishing it as a preferred first-line regimen for eligible patients. However, not all patients are candidates for this combination, emphasizing the necessity of individualized treatment strategies. Future research should focus on managing treatment-related adverse events and developing personalized therapies to maximizing efficacy while minimizing toxicity.

Medical errors occur around 5% of admissions, sometimes resulting in serious outcomes. They tend to provoke lawsuits against healthcare workers, causing much concern. Nowadays in Korea, the number of lawsuits is increasing considerably, thus enhancing the need of solutions for this problem.Current Concepts: The present responses of healthcare workers in medical errors are denial. Patients become dissatisfied more against such attitude, increasing possibility of lawsuits. Therefore we need to adopt new strategies for solving this problem, which fortunately have been developed and applied over many countries.Discussion and Conclusion: The harmful results from medical errors can’t be presumed intentional. Further, error-prone culture of workplace act together in raising the events. So, the recent increasing trend of mindless legal judgements based upon considering the consequences of the events seem to be unreasonable. Safety culture being developed and established in many countries intends to prevent diverse adverse events and make trustworthy healthcare system. The major components of safety culture are (1) Frank disclosure of errors to meet the wishes of patients which corresponds to ethical responsibility regarding delegated medical work; (2) Just culture giving fair considerations to medical personnel regarding the errors; (3) Safety culture at the organizational level including incident reporting system which can only be worked well through the atmosphere of open communication and adherence to practice standards. However in Korea, considering realistic situations of patients having much distrust against medical personnel and thus easily making civil and criminal lawsuits, it would be more reasonable to put disproportionate legal lawsuits in order.